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Abstract 
Available evidence points toward an epigenetic process in Alzheimer’s disease. This 
thesis describes the research that was done to investigate changes in DNA methylation 
using an in vitro model of the disease. Although the results indicated no global changes in 
methylation levels after treating differentiated IMR-32 cells with beta amyloid, there 
were several regions of the genome that changed their methylation status. Gene ontology 
studies revealed that these regions are associated with neuronal differentiation and cell 
fate genes, thus providing a possible model for the contribution of beta amyloid to the 
development of Alzheimer’s disease. This study provides incentive to further study the 
epigenetic processes in Alzheimer’s disease and explore avenues to reverse such 
epigenetic changes.  
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Effects of Beta Amyloid on the DNA Methylation Status of an in Vitro Model 
of Alzheimer’s Disease 
Introduction 
Statement of the Problem 
The classic hallmarks of Alzheimer’s disease (AD) are the presence of 
neurofibrillary tangles (NFTs) and beta amyloid plaques. The terminal abnormal cellular 
conditions of this neurodegenerative disease are well researched; however, the genetic 
factors that may play a role in the development of the disease remain less clear. 
Moreover, the epigenetic factors that cells use to modulate the DNA sequence are even 
less clear. Although several lines of evidence suggest that epigenetic modifications, like 
DNA methylation, might play a role in Alzheimer’s disease, it remains to be determined 
if an epigenetic signature can be a telltale sign of AD development. 
The identification of epigenetic marks associated with AD development would 
provide excellent diagnostic markers for mapping AD progression and propose an 
epigenetic model to how show AD initially begins. In addition, a non-mutational, 
reversible process like DNA methylation would be vulnerable to the development of 
epigenetic therapeutics aimed at preventing or even undoing age-related changes to the 
genome. This thesis represents a novel line of research that may lead to significant 
progress in our understanding of AD progression and the biology of aging. 
Background 
Epigenetics. The cytosine of the 5’-CpG-3’ dinucleotide serves as the target for 
DNA methylation. Approximately 40% of human promoters contain CpG rich domains 
that typically contain low levels of DNA methylation (1, 2). The presence or absence of 
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the methyl mark across the DNA landscape can regulate the binding of various 
transcription factors to the promoter regions. For instance, the transcription factor Ets-1 
binds to its recognition sequence upstream of the Foxp3 gene promoter only when that 
sequence is devoid of DNA methylation. Because this sequence is normally methylated 
in most tissues, Ets-1 binding (and thus Foxp3 promoter activation) is typically inhibited 
(3). On the other hand, transcriptional repressors like MeCP2 require CpG methylation 
near promoter regions in order to bind DNA and ultimately repress transcription (1). 
Since CpG methylation can either prevent the binding of factors that promote 
transcription or enable the binding of transcriptional repressors, gene silencing is the 
major biological outcome of DNA methylation (4) although exceptions are sure to exist 
(5). 
Unlike mutational changes in the genome, epigenetic marks (such as the post-
translational modification of histones and the methylation of cytosines) can dynamically 
alter the local chromatin environment which results in dynamic changes in gene 
expression and genomic stability (see (6) for a review). Interestingly, changes in genomic 
methylation patterns are strongly associated with various disease states such as cancer 
and syndromes involving mental retardation (7). These disease-associated epigenetic 
changes produce an overall hypomethylated genome, although some portions of the 
genome have restricted regions of CpG hypermethylation (8, 9). Understanding where 
these specific epigenetic changes have occurred will not only highlight the genomic 
regions most likely responsible for the overall disease pathology, it will also provide 
useful targets for future therapies. 
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Alzheimer’s Disease. Alzheimer’s disease (AD) is a neurodegenerative disorder 
characterized by the presence of neurofibrillary tangles (NFTs) and amyloid plaques. The 
production of these structures results, in part, by the accumulation of 
hyperphosphorylated tau (10-13) and Aβ peptide (14, 15), respectively. While normal tau 
proteins add stability to microtubule structures, hyperphosphorylated tau leads to 
microtubule disassembly and a breakdown of the neuronal cytoskeleton (11). Likewise, 
Aβ deposits can produce neuronal, endothelial and glial cell death through several 
apoptotic pathways (16, 17). Even though several of the aberrant cellular conditions of 
AD are well known, the initial genetic factors which contribute to the development of AD 
are unclear. 
Gene expression studies have been conducted to determine some of the 
transcriptional changes that result from artificial Aβ peptide treatments. These studies 
were quite limited in their scope either because they were conducted in undifferentiated 
neuroblastoma cells (18) or because only a portion of the transcriptome (1,176 genes in 
mouse) was examined (19). Although more expression data are needed to accurately 
describe the status of AD cells, the underlying cause of these differences in promoter 
activity is even more important. This includes the epigenetic contributions, such as DNA 
methylation, which serve to modulate base-line DNA sequences in the neuronal cells. 
Epigenetics and AD. Several lines of evidence suggest that epigenetic 
modifications, like DNA methylation, play a role in AD. First, late onset Alzheimer’s 
disease, which represents over 90% of AD cases, appears sporadic in nature with no 
known genetic cause (20). Consistent with this, the inheritance pattern of AD in twins 
suggests a non-Mendelian mode of acquiring the disease (21-23) indicating that DNA 
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sequence alone does not explain AD development. Second, evidence of a parent-of-
origin effect has been described for AD identifying several genomic regions that are 
transmitted through the maternal line to affected individuals (24). The requirement of an 
environmental contribution (in this case being the maternal germ line) is consistent with 
an epigenetic mechanism (25). It is interesting to note that one of the most common 
mechanisms of parent-of-origin effects is “genomic imprinting” mediated by DNA 
methylation (26). Third, studies in mice and humans suggest a global change in DNA 
methylation when comparing AD subjects to their control counterparts. In humans, 
monozygotic twins discordant for AD displayed differential DNA methylation levels in 
the anterior temporal neocortex, a region severely affected in AD (27). The regions of the 
brain not affected by AD displayed identical DNA methylation levels demonstrating the 
specificity of this result. The specific reduction of DNA methylation in the AD twin may 
provide a rationale for the link between folate deficiency and AD, since one of the normal 
functions of folate is to donate methyl groups for DNA methylation reactions (28). 
Finally, the expression levels of several AD-associated genes (APP, β-APP cleaving 
enzyme, and neprylisin) are regulated based on the DNA methylation status of their 
respective promoters (29, 30). It is important to note that although AD is associated with 
a global hypomethylation of the genome, the neprylisin (31) promoter actually becomes 
hypermethylated in murine cerebral endothelial cells treated with Aβ (30). This evidence 
demonstrates that a gene can be affected by an epigenetic change that increases or 
decreases its normal methylated state. NEP (neprylisin) expression is significantly 
reduced in AD brains most likely due to methylation-dependent silencing (30, 32). Taken 
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together, these data strongly suggest that DNA methylation plays a key role in the 
development of AD.  
Although the information presented above provides a strong link between DNA 
methylation and AD, the specific pattern of genomic methylation has yet to be 
determined in an AD model system for all human promoters. Furthermore, it remains to 
be determined if an epigenetic signature can be indicative of AD development and 
possibly useful in the diagnosis and treatment of the disease. Revealing the specific 
regions of epigenetic change will not only shed light on the molecular process of AD 
development, but it will also indicate the regions most vulnerable to the development of 
future AD therapeutics. 
Determining Methylated DNA Sequences  
Several methods have been described that detect the presence of methylated 
DNA. The methods used for determining methylated CpGs will be discussed here. 
Bisulfite sequencing (33) utilizes the chemical differences between methylated and 
unmethylated cytosine. Sodium bisulfite reacts with normal cytosine (unmethylated) to 
form a sulfonated cytosine that can easily be deaminated to form sulfonated uracil. 
Following the removal of the sulfonate group by alkaline conditions, the template can be 
used in a standard polymerase chain reaction (PCR) reaction using Taq polymerase. 
Since Taq recognizes uracil as thymine, the resulting PCR product will have a thymine at 
locations corresponding to unmethylated cytosines. Methylated cytosines, on the other 
hand, are protected from the chemical transitions to uracil so no changes in PCR product 
are detected (see (34) for review). Although reliable, this method is not easily adapted to 
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meet the requirements of a genomic-sized examination since sequencing at this scale is 
quite expensive. 
A spin off of the bisulfite sequencing method utilizes PCR primers to discriminate 
between methylated and unmethylated templates (35). Primers are designed to overlap 
with the CpG region of interest. After the template is treated with sodium bisulfite to 
convert unprotected cytosines to uracil, methylation-specific primers are used to anneal to 
the cytosines that remain (due to their protection by methylation). A PCR product 
indicates the primer could anneal and reveals the methylation status. Like bisulfite 
sequencing, this method is also not easily adapted to a genomic-scale based on the time 
and expense associated with high throughput PCR. 
 The methylated DNA immunoprecipitation (MeDIP) method (36) uses an 
antibody to capture DNA fragments by way of their methylated cytosines. The capture of 
specific regions is expressed as a purification enrichment and can be determined using 
PCR or by hybridizing the material to genomic chip arrays. The latter platform allows the 
global determination of methylated regions. Because this method does not detect 
unmethylated cytosines, a failure to detect a CpG region of interest could be due to its 
hypomethylated state or a technique problem in the purification process. 
 Other methods of DNA methylation determination utilize the specificity of 
restriction endonucleases for a particular CpG methylation state (methylation-sensitive 
restriction enzyme; MSRE) followed by PCR analysis. An example of an MSRE is HhaI, 
which recognizes and cuts 5’-GCGC-3’ sequences only when they are unmethylated (37). 
PCR of the region will produce a visible product only when the included CpG is 
methylated and thus protected from enzymatic digestion. This assay requires additional 
DNA METHYLATION   11 
PCR controls to determine if failed PCR runs are due to poor primer design or if the 
region is indeed hypomethylated. 
This shortcoming can be resolved when two MSREs, with different methylation 
sensitivities, are used. For example, HpaII and MspI are isoschizomers that both 
recognize 5’-CCGG-3’ sequences. HpaII digestion is blocked when these sequences are 
methylated, while MspI is insensitive to the methylation status of the recognition site. 
When these fragments are cohybridized to genomic microarrays, (described as HpaII tiny 
fragment Enrichment by Ligation-mediated PCR; or HELP assay) intergenomic and 
intragenomic comparisons concerning DNA methylation can be made (38). Because this 
method can detect methylated and unmethylated regions on a genomic scale, the HELP 
assay is the method of choice for this study. 
Materials and Methods 
Overview 
Figure 1 outlines the methods used to obtain the results. Briefly, cultured IMR-32 
human neuroblastoma cells were differentiated and subsequently treated with beta 
amyloid (Aβ). DNA from undifferentiated, differentiated, and Aβ-treated will be referred 
to as undiff DNA, diff DNA, and Aβ DNA throughout the rest of this thesis, respectively. 
DNA from each group was isolated, purified and then digested with either HpaII of MspI 
restriction endonucleases. The DNA was then purified again and ligated to two sets of 
adapters of known sequences. Ligation-mediated PCR was then used to amplify all 
samples. A final purification procedure was performed before the samples were sent to 
NimbleGen for fluorescent labeling and co-hybridization on promoter microarray. Raw 
data from the microarrays were processed with computer software to  
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determine and graph HpaII/MspI ratios for each probe. Site-specific PCR was then 
performed on several randomly chosen loci to validate the microarray data and establish 
its biological significance. Regions of significant change in methylation were mapped to 
nearby genes, which in turn were annotated to their corresponding cellular processes. 
Cell Culture 
Cholinergic IMR-32 human neuroblastoma cells (39) were grown and 
differentiated according to the procedure outlined by Curran et al. (40). The cells were 
depleted of fibroblasts through incubation with immunomagnetic anti-fibroblast 
microbeads followed by separation with LD MACS columns, following the 
recommendations of the manufacturer. The cells were maintained in culture in 
proliferation medium (DMEM + glutamax, 5% FCS, 100 U/ml penicillin-streptomycin, 
and 10 µg/ml gentamicin) at 37°C in an atmosphere of 5% CO2. The cells were plated at 
a density of 5 × 105 cells/15 cm plate and grown for 48 hours in this proliferation media. 
The proliferation media was then replaced by differentiation media (DMEM with 
glutamax, 2% FCS, 2mM sodium butyrate, 100 U/ml penicillin-streptomycin, and 10 
µg/ml gentamicin). The cells were maintained in differentiation media for 7 days, and 
then treated with 25 µM Aβ1-40 peptide prepared as described in Chen et al.(30) or 
vehicle for 48 hours. The cells were then rinsed with cold PBS (phosphate-buffered 
saline), harvested by scraping, pelleted by centrifugation in 1.5 ml Eppendorf tubes, and 
stored at -80°C. 
DNA Isolation and Purification 
The undifferentiated, differentiated, and Aβ-treated cell pellets were thawed and 
kept on ice until they were treated with 478 µl of stop buffer (20% SDS, 5M NaCl, 
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.5MEDTA), 20 µl protease K (2.5 mg/ml), and 2 µl RNase. The reagents were mixed 
with the pellets by gentle agitation and the tubes were incubated in a 42°C water bath 
overnight.  
Each sample was treated with 500 µl of phenol-chloroform-isoamyl alcohol 
(PCIAA) and incubated on a rotary wheel for 10 minutes at 37°C. The samples were then 
separated into an organic and aqueous layer by centrifuging at 17,000×g for 5 minutes. 
The aqueous layer containing the DNA in each sample was transformed to new 1.5 ml 
Eppendorf tubes. This process was repeated once to ensure DNA purity.  
To precipitate the DNA, 3× the sample volume in 100% ethanol was added along 
with 1/10 the sample volume in 3M sodium acetate, and .5 µl of glycogen (20 mg/ml) to 
each sample. The samples were then centrifuged at 17,000×g for 1 hour. The supernatant 
was removed and the pellets were subsequently washed gently with 70% ethanol. The 
pellets were finally resuspended in 200 µl of deionized water. The DNA in each sample 
was then quantified using UV spectroscopy. 
Digestion  
Each sample was digested with HpaII and MspI in separate reactions. Each 
reaction contained 1 µg of DNA and 4 µl of HpaII (10,000 U/ml) with 20 µl of New 
England Biolabs Buffer 1, or 2 µl of MspI (20,000 U/ml) with 20 µl of NEB 4 and. The 
reactions were brought to a final volume of 200 µl with deionized water and incubated 
overnight in 37°C. The DNA from each sample was then purified as described above and 
resuspended in 15.5 µl of 10 mM Tris-HCl (pH 8).  
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Ligation 
To avoid degradation or re-annealing of the sticky ends, the ligation was 
performed immediately after the digestion. Two sets of adapters were used: NHpaII12 
(5’-CGGCTTCCCTCG-3’), NHpaII24 (5’-GCAACTGTGCTATCCGAGGGAAGC-3’), 
JHpaII12 (5’-CGGCTGTTCATG-3’), JHpaII24 (5’-
CGACGTCGACTATCCATGAACAGC-3’). The 24-mer and 12-mer oligonucleotides of 
each set were annealed together in preparation for the ligation. Ligation was performed 
on HpaII and MspI digested undiff DNA, diff DNA, and Aβ DNA. Reactions were 
carried out in PCR tubes and consisted of 6 µl of 5× T4 ligase buffer (250 mM Tris-HCl 
(pH 7.6), 50 mM MgCl2, 5 mM ATP, 5 mM DTT, 25% (w/v) polyethylene glycol-8000, 
Invitrogen), 15.5 µl digested DNA, 4 µl of 50 µM pre-annealed JHpaII linkers, 4 µl of 
µM pre-annealed NHpaII linkers, and 1 µl of T4 DNA ligase (4 U/ µl). The reactions 
were put in a thermocycler at 16°C overnight. The reactions were then diluted to 10 ml 
by 10 mM Tris-HCl (pH 8). 
LM-PCR 
The MspI digested DNA used in the amplification was half the volume of the 
HpaII digested DNA. This is due to the difference in complexity of fragments in the MspI 
digested DNA, which will cause these fragments to amplify and saturate the solution in 
the PCR faster and undergo “extra” cycles without amplification. This makes the sample 
susceptible to unwanted artifacts. This increased complexity in MspI fragments, and 
circumventing this issue by use half as much MspI digested DNA as HpaII digested DNA 
was previously reported(38). The LM-PCR reactions contained 5 µl of HpaII digested 
DNA or 2.5 µl of MspI digested DNA, .5 µl of JHpa 24-mer oligonucleotide, .5 µl of 
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NHpa 24-mer oligonucleotide, 25 µl of Supermix (Bio-Rad), and brought to a final 
volume of 50 µl with deionized water. The LM-PCR scheme began with an initial 
extension step at 72°C for 10 minutes, 15-20 cycles of annealing at 95°C for 30 seconds 
and 72°C for 3 minutes, and a final extension step at 72°C for 10 minutes.  
Purification 
The reactions were purified using Qiagen’s QIAquick PCR Purification Kit (50) 
according to the manufacturer’s instructions and DNA was quantified using UV 
spectroscopy.  
Microarray  
Five 385K DNA Methylation microarrays were purchased from Roche 
NimbleGen to hybridize 2 undiff DNA samples, 2 diff DNA, and 1 Aβ DNA. Following 
quality control requirements by Roche NimbleGen for human DNA, all samples were 
amplified to and purified to achieve a final mass of at least 4 µg of DNA and a 
concentration of at least 250 ng/µl.  
Data Analysis  
The raw microarray data from Roche NimbleGen was processed using Matlab 
2011. First, correlation graphs were generated to examine the relationship between the 2 
undiff DNA microarrays and between the 2 diff DNA microarrays. Each array contained 
4,288 random probes designed by Roche NimbleGen for control purposes. The 
background fluorescence threshold was taken as 2.5 mean absolute deviations (MAD) 
above the median fluorescence signal of the random probes (41, 42). For a probe to be 
considered valid, both of its HpaII and MspI DNA signals have to be above the threshold, 
and in all 3 conditions (undiff DNA, diff DNA, and Aβ DNA). An HpaII/MspI ratio 
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histogram was generated for each condition (undifferentiated, differentiated, and Aβ-
treated). The undifferentiated and differentiated data were an average of 2 microarray 
data sets for those conditions. The histograms were mean-centered and the x-axis was 
converted from linear scale to log2.  
Site-specific Confirmations  
Site-specific qPCR confirmations were used to validate the microarray data and 
show their biological significance. Undiff, diff, or Aβ DNA was digested with HpaII and 
MspI in separate reactions as described above. An “uncut” control was included to serve 
as a positive control for maximum amplification possible. The recipe for the uncut 
digestion reaction was identical to that of MspI except that 2 µl of 50% glycerol were 
added instead of the enzyme. The samples were subsequently purified as previously 
described and resuspended in 200 µl of deionized water.  
Initially, confirmations were aimed at exploring probes that exhibited 
significantly more or less HpaII/MspI ratio than the mean. Another focus of those 
confirmations was probes that showed the greatest changes in their HpaII/MspI ratio 
between diff and Aβ DNA. Primers were designed around the closest 5’-CCGG-3’ to 
such probes using Primer3 (http://frodo.wi.mit.edu/). The PCR product size range was 
chosen to be between 80-140 bp, the primer Tm was 60±2, and the primer size was 20±2 
bp. All other criteria were left as the default settings by the software. The 25 µl qPCR 
reactions contained .015-.025 µg of HpaII or MspI-digested DNA or uncut DNA, 12.5 µl 
Supermix, and forward and reverse primers with a final concentration of .625 µM each. 
Reactions lacking DNA template were also included as control for primer self-annealing 
and amplification. Amplification was performed using a BioRad MJ Mini Personal 
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Thermal Cycler. The touchdown qPCR scheme began with an initial melting step at 95°C 
for 5 minutes. The first cycle was repeated 19 times and consisted of a melting step at 
94°C for 10 seconds, followed by annealing at 69°C for 30 seconds, and a final extension 
step at 72°C for 30 seconds. The annealing step decreased by .5°C each cycle. The 
second cycle followed immediately and consisted of a melting step at 94°C for 10 
seconds, annealing at 59°C for 30 seconds, and then an extension step at 72°C for 30 
seconds. This second cycle was repeated 24 times with a constant annealing temperature, 
and was followed by a final extension step at 72°C for 5 minutes. The amplification 
graphs were generated by BioRad CFX Manager 2.0. The quantification cycle (Cq) 
values were obtained by positioning the artificial horizontal line within the linear phase 
of amplification for all three curves - uncut, MspI, and HpaII DNA – for each primer pair 
(Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Determining Cq values. The graph represents a typical graph generated at 
the end of a qPCR run. Each curve represents relative fluorescence readings from one 
well after each cycle. The artificial threshold line is positioned so that it is across the 
linear phase of all curves in question for a given primer pair. The point at which the 
threshold line intersects with a curve represents the Cq value for that curve.  
UNCUT 
HPAII 
MSPI 
THRESHOLD 
Cq 
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Gene Ontology 
Gene symbols were linked to the 222 most changing regions, 111 regions 
becoming hypomethylated and 111 regions becoming hypermethylated, by plugging the 
region names into GREAT, a region/gene association and annotation software developed 
by Stanford University and Bejarano Lab (43). Human genome 18 was used for the 
species assembly and the whole genome for the background regions. This software 
developed graphs representing the number of associated genes per region, distance to 
TSS, and absolute distance to TSS. Under the global controls options, “View all region-
gene associations” was chosen to obtain all of the gene symbols for the inputted regions. 
These gene symbols were then plugged into GeneCodis (44-46), a gene annotation 
website; homosapiens was used as the organism and biological processes was selected for 
genome wide assessment. The gene symbols of the regions becoming more 
hypomethylated, more hypermethylated, a combined list, and a random list of 111 
regions from the microchip data were assessed using the following G.O. requirements: 
level 7 (the most stringent), a minimum of 3 genes associated with that ontology, a chi 
square value that was lower than the lowest obtained chi square value from the random 
list. False discovery rate was used to find a corrected chi square value. The enrichment 
value from which the chi-square value was obtained was calculated by dividing the ratio 
of genes for a gene ontology in the list to the total number of genes in the list by the ratio 
of genes for that gene ontology in the genome to the total number of genes in genome. 
 
Number of Genes for G.O. in List
Number of Genes in List

 Total Number of Genes for G.O.
Total Number of Genes in Genome

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The gene ontologies that met these requirements and were associated with the 
central nervous system were charted and linked with their gene symbols.  
Results 
Global DNA Methylation Distribution in Neurons Remains Largely Unchanged 
after Aβ Treatment in Vitro 
IMR-32 human neuroblastoma cells were differentiated and subsequently treated 
with Aβ or vehicle for 48 hours. DNA from experimental and control cells was isolated, 
differentially digested with HpaII and MspI, amplified, and hybridized to a promoter 
microarray. Analysis of the microarray data revealed a bimodal frequency distribution of 
the fluorescent loci in the control sample, a distribution that remains largely unchanged in 
the Aβ treated sample (r=.9870) (Figure 3A and B). The bimodal distribution of the data 
is consistent with the expectation that CpG dinucleotides fall into hypomethylated or 
hypermethylated categories. The overall consistency of the distribution after Aβ 
treatment suggests that only a select few genetic loci – corresponding to certain cellular 
processes – are epigenetically affected by Aβ. 
Site-specific qPCR Confirms the Microarray Data 
Since DNA methylation decreases from left to right along the x-axis in Figure 3A 
and B, it is expected from a probe which has an HpaII/MspI ratio higher than the average 
of the red curve to have a nearby CCGG that is less methylated in comparison to a CCGG 
laying close to a probe with a ratio lower than the mean of the blue curve. To confirm the 
predictions of the microarray, regions (A “region” is a chromosomal range that 
encompasses a group of neighboring probes. These chromosomal ranges were specified 
by NimbleGen in the raw data output and serve as “parent” designations for the included  
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Figure 3. Global DNA Methylation Distribution in Neurons Remains Largely 
Unchanged After Aβ Treatment in Vitro. (A and B) The log2 HpaII/MspI ratios for 
the control and Aβ-treated microarray probes are plotted as frequency distributions. 
The data are mean-centered at zero (vertical grey line), with negative ratios and 
positive ratios signifying loci more and less methylated than the mean level of 
methylation, respectively. The blue and red curves represent the two components of 
the bimodal distribution. Each curve shows the probability of the data of each bin 
belonging to the left peak or the right peak of these bimodal distributions. (A) The 
mean HpaII/MspI ratios of the blue and the red curve are -0.66 and 1.76, respectively. 
(B) The mean HpaII/MspI ratios of the blue and the red curve are -0.76 and 1.95, 
respectively. 
 
More Methylation 
More Methylation 
Less Methylation 
Less Methylation 
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probes) were randomly chosen from a list of candidates that have 2-5 probes with an 
HpaII/MspI ratio higher than the mean of the red curve or lower than the mean of the 
blue curve. In those regions, we used qPCR to target a CCGG that was (1) lose to the 
probe(s) which qualified the region for this analysis and (2) had an appropriate 
surrounding DNA complexity to facilitate specific primer design.  
Figure 4A showcases a region that has two probes with ratios higher than the 
average of the red curve in the control sample frequency distribution (Figure 3A). For 
comparison, Figure 4B shows a region that has 4 probes with ratios lower than the 
average of the blue curve in the same frequency distribution. Accompanying qPCR 
graphs of the highlighted CCGGs show approximately 40 times difference in 
methylation. In other words, in the population of differentiated IMR-32 cells, the CCGG 
in Figure 4A is 40 times less methylated than the CCGG in Figure 4B.  
We performed the same confirmation experiments on data from the Aβ 
microarray (Figure 5A and B). The chromosomal region in Figure 5A has 5 probes with 
HpaII/MspI ratios higher than the average of the red curve in Figure 3B. The region in 
Figure 5B has 3 probes with ratios lower than the average of the blue curve in Figure 3B. 
Looking at the two accompanying qPCR graphs, it is apparent that the CCGG in Figure 
5B is approximately 15 times more methylated than the CCGG in Figure 5A in the 
population of Aβ-treated neurons. These results demonstrate that the probe ratios are 
indicative of actual methylation levels of nearby CpGs. Therefore, biologically 
significant conclusions can be reliably obtained from the microarray data. 
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Figure 4. Site-specific qPCR Confirms the Microarray Data (Control Sample). (A 
and B) The landscapes of microarray regions selected for confirmations are plotted 
with purple bars representing the probes and blue circles showing the CCGG loci in 
those regions. The qPCR results for the chosen CCGGs (red circles) are generated by 
setting the 2^(-(Cq)) of the MspI-digested DNA qPCR curve to “1” and setting the 
HpaII bar to represent the value of 2^(-(CqHpaII-CqMspI)). 
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Figure 5. Site-specific qPCR Confirms the Microarray Data (Aβ Sample). (A and 
B) The landscapes of microarray regions selected for confirmations are plotted with 
purple bars representing the probes and blue circles showing the CCGG loci in those 
regions. The qPCR results for the chosen CCGGs (red circles) are generated by setting 
the 2^(-(Cq)) of the MspI-digested DNA qPCR curve to “1” and setting the HpaII bar 
to represent the value of 2^(-(CqHpaII-CqMspI)). 
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Aβ Induces High Changes in Methylation Levels in a Subset of Loci 
Although Figure 3 showed that the global DNA methylation status of the control 
sample genome does not change after treating the cells with Aβ, specific loci may still 
undergo change in methylation levels in response to Aβ treatment. Subtracting the 
HpaII/MspI ratios of the control microarray from the Aβ microarray produces the normal 
distribution shown in Figure 6A. Probes from only 0.05% of either end of the normal 
distribution were used for further confirmations and gene ontology analysis (Figure 6B 
and C). This portion represents a group of probes that changed their signal the most in 
response to Aβ treatment. With such stringency, we are eventually ensuring the selection 
of the biological processes that are most affected by Aβ treatment. 
Aβ-induced Probe Ratio Changes Correspond to CpG Methylation Changes 
Figures 4 and 5 demonstrate that the control sample and Aβ sample microarrays 
are successful in predicting CpG methylation differences within each sample. However, 
before proceeding with gene ontology analysis, it was necessary to confirm that a ratio 
change of the same given probe between the control sample and the Aβ sample 
microarrays corresponds to a same-CpG change in methylation between the control DNA 
and Aβ-treated DNA. Probes were chosen randomly from the “upper” and “lower” 0.05% 
of the most changing probes and qPCR was performed on the upstream and downstream 
CCGGs flanking each chosen probe in differentiated DNA and Aβ-treated DNA. Figure 
7A contains a landscape of a region with a probe that shows a significant increase in 
HpaII/MspI ratio, and Figure 7B shows a region with a probe that displays a significant 
decrease between the control sample and the Aβ-treated sample. The 
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Figure 6. Aβ Induces High Changes in Methylation Levels in a Subset of Loci. (A) 
The data from the control microarray are subtracted from the Aβ data, and the result is 
plotted as a frequency distribution. The two vertical lines represent the “upper” and 
“lower” 0.05% cutoff positions in respect to the rest of the distribution. (B) A close-up 
frequency distribution of the “lower” 0.05% of the probes with the highest decrease in 
HpaII/MspI ratio (C) A close-up frequency distribution of the “upper” 0.05% of the 
probes with the highest increase in HpaII/MspI ratio.  
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Figure 7. Aβ-induced Probe Ratio Changes Correspond to Methylation Changes 
at Nearby CpGs. (A and B) The landscapes of microarray regions selected for 
confirmations are plotted with purple bars representing the (Aβ-control) value for the 
probes and blue circles showing the CCGG loci in those regions. The “control” and 
“AB” bars in the qPCR graphs represent the value of 2^(-(CqHpaII-CqMspI)) in the 
control and Aβ sample DNA, respectively.  
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accompanying qPCR graphs for each region demonstrate that the change in probe ratios 
are confirmed with parallel changes in CpG methylation levels after Aβ treatment.  
Aβ alters the DNA Methylation of Cell Fate Genes 
The low number of high changes in probe ratios as seen in Figure 6 suggests that 
Aβ alters only a handful of cellular processes epigenetically in vitro. To shed light on 
these cellular processes, we mapped the 222 chromosomal regions that contained the 
highly changing probes to nearby genes using GREAT online software. Some regions 
were as close as 70-300 bp away from the nearest genes, while other regions were more 
than 150,000 bp away (data not shown). The output gene symbols were then annotated 
using GeneCodis online software. GeneCodis also generated p-values indicating the 
likelihood of several genes belonging to the same gene ontology being inour list of 
annotated genes. The results showed high levels of enrichment for genes associated with 
neuron differentiation, neurogenesis, and apoptosis (Table 1). Although Aβ treatment 
does not change the global DNA methylation status of the genome, it seems to effectively 
target select loci that have high impact on the fate of the cells. The probability that a 
number of genes in one ontology would appear in our list together can be contrasted with 
the probability of a random number of genes and their ontologies appearing in a list the 
same size as ours (Table 1).  
To shed light on the probe ratio changes in respect to the landscape of one of our 
significant genes, we plotted the TSS of DLX1 and the regions associated with it, 
including the most significant changing probe that mapped to DLX1 in GREAT (Figure 
8). The five regions surrounding the TSS showed small ratio changes in both directions.  
 
DNA METHYLATION 
 
 
 
 
 
 
Table 1. Aβ alters the DNA Methylation of Cell Fate Genes
of the “upper” and “lower” 0.05% most changing probes after A
mapped to the closest known genes. The generated list of gene names was annotated 
using GeneCodis. The p
genes belonging to the same ontology to be in the same list of genes. A list of random 
genes of the same size as our list was also entered in GeneCodis to generate p
associated with the likelih
the same size as ours. For stringency purposes, all ontologies listed have a p
smaller than the p-value of the random list except for the first two p
high due to the fact that all the genes that belong to those ontologies in the genome are 
in our list. Enrichment was calculated using the compound fraction described in the 
Materials and Methods section.
 
 
. Parent region names 
β treatment were 
-values in this table represent the likelihood of a number of 
ood of random genes with random ontologies being in a list 
-values which are 
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-values 
-value 
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The most significant probe lies in a region that is approximately 6000 bp 
downstream of the TSS, indicating a high loss of methylation at that region. 
Discussion 
Our data reveal that the global DNA methylation status of the genome does not 
change when differentiated IMR-32 cells are treated with Aβ in vitro. However, lack of a 
global change in DNA methylation does not rule out changes at specific loci. Indeed, we 
confirmed that Aβ induces change in DNA methylation at discrete loci which are 
associated with cell fate genes such as neuron differentiation and apoptosis.  
When we observed a change in the HpaII/MspI ratio of a given probe, it was not 
possible to pinpoint with absolute certainty which CCGG around that probe was changing 
its methylation level and producing the change in the ratio. For that reason, we chose our 
Figure 8. High Loss of Methylation Downstream of DLX1 TSS. The figure shows a 
landscape of the five regions around the TSS of DLX1. The y-axis represents (Aβ-
control) probe ratios and the x-axis represents the chromosomal position. The 
rightmost region was the region that led to DLX1 in GREAT.  
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method of testing one downstream and one upstream CCGG of the probe of interest. It 
should be noted that it could be changes in methylation in farther CCGG that produce the 
changes in probe ratios. However our high rate of confirmation on the upstream and 
downstream CCGGs reveals the high likelihood that changes in DNA methylation by Aβ 
are not pinpoint processes, but when there is a methylation change at one CpG it is likely 
that neighboring CpGs follow.  
After mapping the microarray regions that showed significant change in 
methylation to nearby genes, we found that some regions were 70-300 bp away from the 
nearest genes, while other regions were more than 150,000 bp away. Although some high 
changes in methylation are fairly distant from the TSS, it is well-established that gene 
regulation can proceed distally through enhancer mechanisms (for review see (47, 48)). 
Future studies can focus on those regions and evaluate their candidacy as possible distal 
enhancer regions. It is also important to note that GREAT software maps regions to the 
closest “canonical” TSS of a given gene. It is possible, then, that GREAT is ignoring 
potentially closer TSS sites. In other words, some of the regions that highly change their 
methylation status in our data may be closer to a nearby gene than the data may seem to 
suggest.  
A previous study by Cobos et. al. shed light on the involvement of DLX 
transcription factors on the migration and differentiation of GABAergic interneurons 
(49). Interestingly, they found that DLX1/2 double mutant mice have interneurons that 
fail to migrate from the subpallium to the cortex and show immature increase in neurite 
growth. These results demonstrated the importance of DLX1 and DLX2 in the repression 
of neurite growth and maintaining a compact cell shape that is necessary for easy 
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migration maneuvers. With these previous findings in mind, our data seems to suggest 
the involvement of Aβ in “de-differentiating” neurons and the consequent loss of their 
specific functions. Such effect could lead to the memory loss and aberrant brain function 
accompanied by AD. We therefore encourage future research to directly examine the 
expression levels of DLX1 in AD brain tissue as that may be a key step in pathogenesis. 
Conclusion 
We can make three conclusions from the results presented herein. First, Aβ 
treatment of differentiated neurons in vitro does not change the global DNA methylation 
levels of the genome. There is an overall consistency in the structure of the distribution of 
methylation levels before and after Aβ treatment. There is also a high correlation in ratio 
values between the control sample probes and the Aβ sample probes of the same loci. 
Second, exposure to Aβ does lead to significant changes in methylation at a subset of 
loci. Although the majority of the loci show largely unchanged methylation levels, some 
loci show high changes in DNA methylation following Aβ treatment. Third, these loci are 
associated with genes involved in neuronal differentiation, neurogenesis, and apoptosis 
control. Therefore, Aβ seems to contribute to AD progression through propagating 
neuronal loss of function and death. 
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